SCHEMBL23395566

SCHEMBL23395566

COc1ccc2cc(-c3cccn3C)oc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.48
▸ APP P05067 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ HPGD P15428 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA3 P07451 1/20 0.45
▸ AKR1B1 P15121 1/20 0.45
▸ CA4 P22748 1/20 0.45
▸ CA6 P23280 1/20 0.45
▸ CA5A P35218 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ F2RL3 Q96RI0 3/20 0.44
▸ GPR55 Q9Y2T6 1/20 0.44
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26292135 0.84 RAB9A (0.38) PTPN1APPALDH1A1HPGDKDM4E
SCHEMBL23395663 0.79 SHBG (0.53) PTPN1APPALDH1A1HPGDKDM4E
SCHEMBL23395654 0.79 F2RL3 (0.33) PTPN1APPALDH1A1F2RL3GPR55
SCHEMBL26298436 0.79 F2RL3 (0.33) PTPN1APPCA12CA1CA3
SCHEMBL25900671 0.76 F2RL3 (0.34) PTPN1APPALDH1A1HPGDKDM4E
SCHEMBL26291598 0.76 S1PR1 (0.36) APPALDH1A1HPGDKDM4ECA12
SCHEMBL26291600 0.76 RAB9A (0.37) APPALDH1A1HPGDKDM4ECA9
SCHEMBL6822627 0.75 NPC1 (0.66) PTPN1APPALDH1A1HPGDKDM4E
SCHEMBL6748778 0.75 APP (0.64) PTPN1APPALDH1A1HPGDKDM4E
SCHEMBL29873464 0.75 APP (0.64) PTPN1APPALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
US-11753387-B2 Compounds for optically active devices Johnson & Johnson Surgical Vision, Inc. (US) 2023-09-12 — — US disclosed
EP-3889135-B1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES AMO Ireland (IE) 2023-08-02 — — EP disclosed
EP-3889135-A1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES Merck Patent GmbH (DE) 2021-10-06 — — EP disclosed
EP-3583092-B1 COMPOUNDS FOR OPTICALLY ACTIVE DEVICES MERCK PATENT GMBH (DE) 2021-05-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753387-B2 Compounds for optically active devices PDE6C, PDE6A, PDE6D PTPN1 4651/4885APP 899/4885ALDH1A1 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback